MA53043A1 - Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation - Google Patents

Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation

Info

Publication number
MA53043A1
MA53043A1 MA53043A MA53043A MA53043A1 MA 53043 A1 MA53043 A1 MA 53043A1 MA 53043 A MA53043 A MA 53043A MA 53043 A MA53043 A MA 53043A MA 53043 A1 MA53043 A1 MA 53043A1
Authority
MA
Morocco
Prior art keywords
methods
thieno
udp
pyridine derivatives
derivatives used
Prior art date
Application number
MA53043A
Other languages
English (en)
Other versions
MA53043B2 (fr
Inventor
Bradford Hirth
Elina Makino
Mark Munson
Sachin Maniar
Sungtaek Lim
Jr Robert H Barker
Mary A Cromwell
John JIANG
Yong-Mi Choi
Sukanthini Thurairatnam
Kwon Yon Musick
James Pribish
Michael Angelastro
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA53043A1 publication Critical patent/MA53043A1/fr
Publication of MA53043B2 publication Critical patent/MA53043B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (i), tel que décrit ici, et des sels pharmaceutiquement acceptables de celui-ci. L'invention concerne également des compositions et l'utilisation de telles compositions dans des procédés de traitement de toute une série de maladies et d'états, en particulier la maladie de krabbe (mk) et la leucodystrophie métachromatique (mld).
MA53043A 2018-10-01 2019-10-01 Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation MA53043B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
PCT/US2019/054085 WO2020072504A1 (fr) 2018-10-01 2019-10-01 Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA53043A1 true MA53043A1 (fr) 2022-08-31
MA53043B2 MA53043B2 (fr) 2024-05-31

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53043A MA53043B2 (fr) 2018-10-01 2019-10-01 Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation

Country Status (15)

Country Link
US (1) US11098056B2 (fr)
EP (1) EP3861000A1 (fr)
JP (1) JP7545979B2 (fr)
KR (1) KR102903997B1 (fr)
CN (1) CN113423711B (fr)
AU (1) AU2019355870B2 (fr)
BR (1) BR112021005914A2 (fr)
CA (1) CA3114722A1 (fr)
CO (1) CO2021005738A2 (fr)
IL (1) IL281811B2 (fr)
MA (1) MA53043B2 (fr)
MX (1) MX2021003794A (fr)
SG (1) SG11202102987VA (fr)
TW (1) TWI821426B (fr)
WO (1) WO2020072504A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302565A (zh) * 2021-02-19 2023-01-16 英商卡爾維斯塔製藥有限公司 酶抑制劑
EP4483954A1 (fr) * 2023-06-29 2025-01-01 Masarykova Univerzita Thieno[3,2-b!pyridines substituées comme inhibiteurs de protéine kinases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
MXPA02001160A (es) 1999-08-04 2002-07-02 Millennium Pharm Inc Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos.
FR2821356A1 (fr) * 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
EP3109249A1 (fr) * 2007-11-15 2016-12-28 YM BioSciences Australia Pty Ltd Composés hétérocycliques contenant de l'azote
MX2011008276A (es) * 2009-02-06 2011-12-14 Elan Pharm Inc Inhibidores de quinasa jun n-terminal.
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
ES2928714T3 (es) * 2015-01-16 2022-11-22 Massachusetts Gen Hospital Compuestos para mejorar el empalme del ARNm
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
SG11201809693SA (en) * 2016-05-05 2018-11-29 Lysosomal Therapeutics Inc SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017214505A1 (fr) * 2016-06-10 2017-12-14 Biomarin Pharmaceutical Inc. Inhibiteurs de la céramide galactosyltransférase pour le traitement de maladies
MY193511A (en) * 2016-11-02 2022-10-17 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
WO2018118838A1 (fr) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Inhibiteurs de la céramide galactosyltransférase pour le traitement de maladies
EP3619209A1 (fr) * 2017-05-04 2020-03-11 Glenmark Pharmaceuticals S.A. Composés hétérocycliques bicycliques substitués utilisés en tant qu'inhibiteurs de nadph oxydase
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物

Also Published As

Publication number Publication date
IL281811B2 (en) 2025-03-01
JP2022508523A (ja) 2022-01-19
US11098056B2 (en) 2021-08-24
MX2021003794A (es) 2021-09-08
BR112021005914A2 (pt) 2021-06-29
AU2019355870B2 (en) 2023-11-16
SG11202102987VA (en) 2021-04-29
TW202035419A (zh) 2020-10-01
IL281811A (en) 2021-05-31
EP3861000A1 (fr) 2021-08-11
KR20210087033A (ko) 2021-07-09
AU2019355870A1 (en) 2021-05-20
CA3114722A1 (fr) 2020-04-09
IL281811B1 (en) 2024-11-01
MA53043B2 (fr) 2024-05-31
CN113423711B (zh) 2024-03-15
KR102903997B1 (ko) 2025-12-26
US20200102324A1 (en) 2020-04-02
WO2020072504A1 (fr) 2020-04-09
TWI821426B (zh) 2023-11-11
CN113423711A (zh) 2021-09-21
CO2021005738A2 (es) 2021-05-10
JP7545979B2 (ja) 2024-09-05

Similar Documents

Publication Publication Date Title
MA58004B1 (fr) Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
MA30412B1 (fr) Composés Pharmaceutiques
MA49235B1 (fr) Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA44674B1 (fr) Inhibiteurs de bromodomaine
MX2025015186A (es) Inhibidores de pi3k y uso de estos
PH12022551359A1 (en) Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
EP2178870A4 (fr) Composés d'indole et d'indazole en tant qu'inhibiteurs de nécrose cellulaire
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA56674B1 (fr) Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
WO2019007696A1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA49127B1 (fr) Dérivés d'indole n-substitués
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
WO2020247298A3 (fr) Dérivés d'indazole 5 -, 6-disubstitués, 1-pyrazolyle, en tant qu'inhibiteurs de lrrk2, compositions pharmaceutiques et utilisations correspondantes
MA53043A1 (fr) Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation
ZA202006439B (en) Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators